Navigation Links
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

cts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including RiVax™,  SGX201, orBec® and LPMTM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is de
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Reports Third Quarter 2009 Financial Results
2. Soligenix to Present at 8th Annual BIO Investor Forum
3. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
4. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
5. Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
6. ERT to Present at the UBS 20th Annual Global Healthcare Services Conference on February 8, 2010
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NeurogesX to Present at J.P. Morgan Health Care Conference
11. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... 2014 Whitehouse Laboratories is pleased ... Morris County (New Jersey) Chamber of Commerce as ... business organization in the North Jersey area, offers ... some key clients in the pharmaceutical and biotechnology ... area. Membership enables Whitehouse Laboratories a higher level ...
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... 2nd Annual MPN Heroes recognition reception on December 5, ... of Hematology’s annual meeting. The MPN Heroes event will ... contributions in the field of myeloproliferative neoplasms (MPNs). ... show "Nashville," will discuss his family's cancer journey at ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... Omaxe Infrastructure &,Construction Private Ltd(OICPL), a wholly owned subsidiary ... the construction of Allopathic Medical,College and Associated Hospital at ... value of the project is Rs250 crores,approx., The ... with total built up area,of 15.66 lac sq ft. ...
... initial listing requirements with NASDAQ; Stock Symbol ... extends cash runway while focusing on ... 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly Sonus ... announced that the Company has completed its ...
... SHANGHAI, China, Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, ... "the,Company"), a leading Chinese firm specializing ... distribution of probiotics products,today announced it ... Square,Pharmaceutical Co., Ltd. ("Square Pharmaceutical") to ...
Cached Biology Technology:Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... of scientists led by Fred Hutchinson Cancer Research Center ... feasibility of large-scale, standardized protein measurements, which are necessary ... The study, to be published Dec. 8 online in ... scientists, targeted protein-detection approach has the potential to systematically ...
... even a mild traumatic brain injury. While the brain may ... suggest that the brain,s protective coverings may feel the ... mouse trauma model, senior author Dorian McGavern, Ph.D., scientist at ... of the National Institutes of Health, watched specific cells mount ...
... Philadelphia have manipulated key biological events in adult blood ... after the newborn period. Because this fetal hemoglobin is ... (SCD), the cell culture findings may open the door ... "Our study shows the power of a ...
Cached Biology News:Novel method could help bring cancer biomarkers to clinic 2Novel method could help bring cancer biomarkers to clinic 3Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease 2
Anti-MD-2 (IN) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
p-Bcl-2 (Thr 74)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
Biology Products: